PMC:7534795 / 76129-76677 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T462","span":{"begin":18,"end":23},"obj":"Chemical"},{"id":"T463","span":{"begin":47,"end":52},"obj":"Chemical"},{"id":"T464","span":{"begin":63,"end":98},"obj":"Chemical"},{"id":"T465","span":{"begin":100,"end":104},"obj":"Chemical"},{"id":"T466","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T467","span":{"begin":131,"end":168},"obj":"Chemical"},{"id":"T468","span":{"begin":189,"end":192},"obj":"Chemical"},{"id":"T469","span":{"begin":204,"end":208},"obj":"Chemical"},{"id":"T470","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T474","span":{"begin":231,"end":235},"obj":"Chemical"},{"id":"T475","span":{"begin":288,"end":291},"obj":"Chemical"},{"id":"T479","span":{"begin":418,"end":429},"obj":"Chemical"}],"attributes":[{"id":"A462","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A463","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A464","pred":"chebi_id","subj":"T464","obj":"http://purl.obolibrary.org/obo/CHEBI_140399"},{"id":"A465","pred":"chebi_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/CHEBI_140399"},{"id":"A466","pred":"chebi_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/CHEBI_132120"},{"id":"A467","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_132120"},{"id":"A468","pred":"chebi_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A469","pred":"chebi_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/CHEBI_81559"},{"id":"A470","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A471","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A472","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A473","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A474","pred":"chebi_id","subj":"T474","obj":"http://purl.obolibrary.org/obo/CHEBI_81564"},{"id":"A475","pred":"chebi_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A476","pred":"chebi_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A477","pred":"chebi_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A478","pred":"chebi_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A479","pred":"chebi_id","subj":"T479","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"}],"text":"Metabolism of n-3 PUFAs also generates another group of highly specialized pro-resolving mediators (SPMs) which include resolvins ‘resolution phase interaction products’ produced from both EPA (E-series, RvE1-2) and DHA (D-series, RvD1-6) as well as protectins and maresins produced from DHA (Serhan et al., 2002; Serhan, Chiang, \u0026 Van Dyke, 2008). Both the COX and LOX pathways are involved in the synthesis of these metabolites with distinct epimers being produced in the presence and absence of aspirin (Mas, Croft, Zahra, Barden, \u0026 Mori, 2012)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T153","span":{"begin":0,"end":10},"obj":"http://purl.obolibrary.org/obo/GO_0008152"},{"id":"T154","span":{"begin":399,"end":408},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"Metabolism of n-3 PUFAs also generates another group of highly specialized pro-resolving mediators (SPMs) which include resolvins ‘resolution phase interaction products’ produced from both EPA (E-series, RvE1-2) and DHA (D-series, RvD1-6) as well as protectins and maresins produced from DHA (Serhan et al., 2002; Serhan, Chiang, \u0026 Van Dyke, 2008). Both the COX and LOX pathways are involved in the synthesis of these metabolites with distinct epimers being produced in the presence and absence of aspirin (Mas, Croft, Zahra, Barden, \u0026 Mori, 2012)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T526","span":{"begin":0,"end":348},"obj":"Sentence"},{"id":"T527","span":{"begin":349,"end":548},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Metabolism of n-3 PUFAs also generates another group of highly specialized pro-resolving mediators (SPMs) which include resolvins ‘resolution phase interaction products’ produced from both EPA (E-series, RvE1-2) and DHA (D-series, RvD1-6) as well as protectins and maresins produced from DHA (Serhan et al., 2002; Serhan, Chiang, \u0026 Van Dyke, 2008). Both the COX and LOX pathways are involved in the synthesis of these metabolites with distinct epimers being produced in the presence and absence of aspirin (Mas, Croft, Zahra, Barden, \u0026 Mori, 2012)."}

{"project":"2_test","denotations":[{"id":"33031856-12391014-84038993","span":{"begin":308,"end":312},"obj":"12391014"},{"id":"33031856-22912397-84038994","span":{"begin":542,"end":546},"obj":"22912397"}],"text":"Metabolism of n-3 PUFAs also generates another group of highly specialized pro-resolving mediators (SPMs) which include resolvins ‘resolution phase interaction products’ produced from both EPA (E-series, RvE1-2) and DHA (D-series, RvD1-6) as well as protectins and maresins produced from DHA (Serhan et al., 2002; Serhan, Chiang, \u0026 Van Dyke, 2008). Both the COX and LOX pathways are involved in the synthesis of these metabolites with distinct epimers being produced in the presence and absence of aspirin (Mas, Croft, Zahra, Barden, \u0026 Mori, 2012)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2189","span":{"begin":14,"end":23},"obj":"Chemical"},{"id":"2190","span":{"begin":189,"end":192},"obj":"Chemical"},{"id":"2191","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"2192","span":{"begin":265,"end":273},"obj":"Chemical"},{"id":"2193","span":{"begin":288,"end":291},"obj":"Chemical"},{"id":"2194","span":{"begin":498,"end":505},"obj":"Chemical"},{"id":"2195","span":{"begin":204,"end":210},"obj":"CellLine"}],"attributes":[{"id":"A2189","pred":"tao:has_database_id","subj":"2189","obj":"MESH:D015525"},{"id":"A2190","pred":"tao:has_database_id","subj":"2190","obj":"MESH:D015118"},{"id":"A2191","pred":"tao:has_database_id","subj":"2191","obj":"MESH:D004281"},{"id":"A2193","pred":"tao:has_database_id","subj":"2193","obj":"MESH:D004281"},{"id":"A2194","pred":"tao:has_database_id","subj":"2194","obj":"MESH:D001241"},{"id":"A2195","pred":"tao:has_database_id","subj":"2195","obj":"CVCL:1045"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Metabolism of n-3 PUFAs also generates another group of highly specialized pro-resolving mediators (SPMs) which include resolvins ‘resolution phase interaction products’ produced from both EPA (E-series, RvE1-2) and DHA (D-series, RvD1-6) as well as protectins and maresins produced from DHA (Serhan et al., 2002; Serhan, Chiang, \u0026 Van Dyke, 2008). Both the COX and LOX pathways are involved in the synthesis of these metabolites with distinct epimers being produced in the presence and absence of aspirin (Mas, Croft, Zahra, Barden, \u0026 Mori, 2012)."}